Loading…
Enhabit, Inc. provides home health and hospice services in the United States. The Home Health segment offers nursing care; physical, occupational, and speech therapy; medical and social work; and home health aide services. This segment also provides patient education, pain management, wound care and dressing changes, cardiac rehabilitation, infusion therapy, pharmaceutical administration, and skilled observation and assessment services; practices to treat chronic diseases and conditions, including diabetes, hypertension, arthritis, Alzheimer's disease, low vision, spinal stenosis, Parkinson's disease, osteoporosis, complex wound care, and chronic pain, along with disease-specific plans for patients with diabetes, congestive heart failure, post-orthopedic surgery or injury, and respiratory diseases; and counseling for patients and their families regarding financial, personal, and social concerns that arise from a patient's health-related problems. Its Hospice segment offers nursing care; pain and symptom management; palliative and dietary counseling; social worker visits; spiritual counseling; and family member bereavement counseling to meet the individual physical, emotional, spiritual, and psychosocial needs of terminally ill patients and their families. The company was formerly known as Encompass Health Home Health Holdings, Inc. and changed its name to Enhabit, Inc. in March 2022. Enhabit, Inc. was founded in 1998 and is headquartered in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.1B | $58M | $-5M | $66M | -0.8% | 2.4% | - |
| 2024 | $1.0B | $-84M | $-156M | $47M | -28.2% | -1.1% | - |
| 2023 | $1.0B | $-17M | $-81M | $45M | -11.5% | -2.3% | - |
| 2022 | $1.1B | $23M | $-40M | $73M | -5.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,071.10 | 1,046.30 | 1,034.80 | 1,060 |
| Cost Of Revenue | 525.60 | 535.60 | 530.80 | 540.20 |
| Gross Profit | 545.50 | 510.70 | 504 | 519.80 |
| Operating Expense | 447.90 | 472.50 | 457.40 | 456 |
| Operating Income | 97.60 | 38.20 | 46.60 | 63.80 |
| EBITDA | 22.50 | -16.50 | -83.60 | 57.90 |
| EBIT | -10.50 | -47.40 | -115.10 | 35.40 |
| Pretax Income | -25.50 | -90.40 | -158 | 1.40 |
| Tax Provision | 12.80 | -11.40 | -4 | 4 |
| Net Income | -40.40 | -80.50 | -156.20 | -4.60 |
| Net Income Common Stockholders | -40.40 | -80.50 | -156.20 | -4.60 |
| Total Expenses | 973.50 | 1,008.10 | 988.20 | 996.20 |
| Interest Expense | 15 | 43 | 42.90 | 34 |
| Interest Income | 0 | 0 | 0 | 0.20 |
| Selling General And Administration | 414.90 | 441.60 | 425.90 | 433.50 |
| Normalized EBITDA | 131.50 | 69.30 | 78.10 | 105.60 |
| Normalized Income | 45.71 | -5.52 | 1.41 | 33.08 |
| Basic EPS | 1.26 | -1.61 | -3.11 | 0 |
| Diluted EPS | 1.26 | -1.61 | -3.11 | 0 |
| Tax Effect Of Unusual Items | -22.89 | -10.82 | -4.09 | -10.02 |
| Tax Rate For Calcs | 0.21 | 0.13 | 0.03 | 0.21 |
| Total Unusual Items | -109 | -85.80 | -161.70 | -47.70 |
| Total Unusual Items Excluding Goodwill | -109 | -85.80 | -161.70 | -47.70 |
| Net Income From Continuing Operation Net Minority Interest | -40.40 | -80.50 | -156.20 | -4.60 |
| Reconciled Depreciation | 33 | 30.90 | 31.50 | 22.50 |
| Reconciled Cost Of Revenue | 525.60 | 535.60 | 530.80 | 540.20 |
| Net Interest Income | -15 | -43 | -42.90 | -33.80 |
| Net Income From Continuing And Discontinued Operation | -40.40 | -80.50 | -156.20 | -4.60 |
| Total Operating Income As Reported | -11.40 | -47.60 | -115.10 | 16.10 |
| Diluted Average Shares | 49.70 | 49.90 | 50.20 | 0 |
| Basic Average Shares | 49.60 | 49.90 | 50.20 | 0 |
| Diluted NI Availto Com Stockholders | -40.40 | -80.50 | -156.20 | -4.60 |
| Minority Interests | -2.10 | -1.50 | -2.20 | -2 |
| Net Income Including Noncontrolling Interests | -38.30 | -79 | -154 | -2.60 |
| Net Income Continuous Operations | -38.30 | -79 | -154 | -2.60 |
| Other Income Expense | -108.10 | -85.60 | -161.70 | -28.60 |
| Other Non Operating Income Expenses | 0.90 | 0.20 | 0 | 19.10 |
| Special Income Charges | -109 | -85.80 | -161.70 | -47.70 |
| Impairment Of Capital Assets | 109 | 85.80 | 161.70 | 47.70 |
| Earnings From Equity Interest | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | -15 | -43 | -42.90 | -33.80 |
| Interest Expense Non Operating | 15 | 43 | 42.90 | 34 |
| Interest Income Non Operating | 0 | 0 | 0 | 0.20 |
| Depreciation Amortization Depletion Income Statement | 33 | 30.90 | 31.50 | 22.50 |
| Depreciation And Amortization In Income Statement | 33 | 30.90 | 31.50 | 22.50 |
| General And Administrative Expense | 414.90 | 441.60 | 425.90 | 433.50 |
| Other Gand A | 414.90 | 441.60 | 425.90 | 433.50 |
| Operating Revenue | 1,071.10 | 1,046.30 | 1,034.80 | 1,060 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Enhabit, Inc.this co. | EHAB | $704M | - | 1.31 | -0.8% | 13.72 |
| BioAge Labs, Inc. | BIOA | $749M | - | 2.32 | -29.6% | -5.11 |
| Castle Biosciences, Inc. | CSTL | $734M | - | 1.53 | -5.1% | -224.72 |
| Absci Corporation | ABSI | $732M | - | 3.77 | -60.8% | -5.15 |
| CBLL | CBLL | $729M | - | 4.65 | -34.4% |
| -10.30 |
| Allogene Therapeutics, Inc. | ALLO | $726M | - | 1.65 | -65.3% | -1.79 |
| Gyre Therapeutics, Inc. | GYRE | $713M | 367.50 | 6.33 | 3.5% | 46.81 |
| Solid Biosciences Inc. | SLDB | $694M | - | 3.09 | -96.8% | -2.97 |
| Ironwood Pharmaceuticals, Inc. | IRWD | $683M | 27.67 | -2.58 | -9.2% | 8.78 |
| Peer Median | - | 197.58 | 2.70 | -32.0% | -4.04 | |